natgillin/translations-raw huggingface dataset:
Hos visse patienter med svækket nyrefunktion (dehydrerede patienter eller ældre patienter) kan samtidig administration af aliskiren og NSAID medføre en forværring af nyrefunktion, inklusive mulighed for akut nyresvigt, som sædvanligvis er reversibel.
In some patients with compromised renal function (dehydrated patients or elderly patients) aliskiren given concomitantly with NSAIDs may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible.
Kombinationen af aliskiren og NSAID kræver derfor forsigtighed, især hos ældre patienter.
Therefore the combination of aliskiren with an NSAID requires caution, especially in elderly patients.
Fødeindtag:
Food interactions:
Måltider med højt fedtindhold har vist at reducere absorptionen af aliskiren betragteligt.
Meals with a high fat content have been shown to reduce the absorption of aliskiren substantially.
Potentiering af ortostatisk hypotension kan forekomme.
Potentiation of orthostatic hypotension may occur.
Antidiabetiske lægemidler (orale midler og insulin):
Antidiabetic medicinal products (oral agents and insulins):
4. 4).
Dosage adjustment of the antidiabetic medicinal product may be required (see section 4.4).
Cholestyramin - og colestipolresiner:
Cholestyramine and colestipol resins:
Absorption af hydrochlorthiazid er nedsat ved tilstedeværelsen af anioniske ionbyttere.
Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.
4. 4).
Thiazide-induced hypokalaemia or hypomagnesaemia favour the onset of digitalis-induced cardiac arrhythmias (see section 4.4).
Administration af et NSAID kan reducere de diuretiske, natriuretiske og antihypertensive virkninger af thiaziddiuretika hos visse patienter.
The administration of an NSAID may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics in some patients.
Pressoraminer (f. eks. noradrenalin):
Pressor amines (e. g. noradrenaline):
Pressoraminers virkning kan reduceres.
The effect of pressor amines may be decreased.
Urinsyregigtmedicin:
Antigout medicine:
Dosisjustering af lægemidler mod urinsyregigt kan være nødvendig, da hydrochlorthiazid kan hæve niveauet af serumurinsyre.
Dosage adjustments of antigout medications may be necessary as hydrochlorothiazide may raise the level of serum uric acid.
En øget dosis af probenecid - eller sulfinpyrazol kan være nødvendig.
Increase in dosage of probenecid or sulfinpyrazone may be necessary.
Samtidig administration af thiaziddiuretika kan øge forekomsten af overfølsomhedsreaktioner over for allopurinol.
Co-administration of thiazide diuretics may increase the incidence of hypersensitivity reactions to allopurinol.
Calciumsalte:
Calcium salts:
Thiaziddiuretika kan øge calciumniveauer i serum på grund af nedsat udskillelse.
Thiazide diuretics may increase serum calcium levels due to decreased excretion.
D- vitaminbehandling) skal ordineres, bør calciumniveauer i serum overvåges og dosis af calcium justeres tilsvarende.
If calcium supplements or calcium-sparing medicinal products (e. g. vitamin D therapy) must be prescribed, serum calcium levels should be monitored and calcium dosage adjusted accordingly.
Curarederivater (f. eks. tubocurarin):
Curare derivatives (e. g. tubocurarine):
Virkningen af ikke- depolariserende skeletmuskelrelaksantia kan potenseres af hydrochlorthiazid.
The effect of non-depolarising skeletal muscle relaxants may be potentiated by hydrochlorothiazide.
Betablokkeres og diazoxids hyperglykæmiske virkning kan forstærkes af thiazider.
The hyperglycaemic effect of beta blockers and diazoxide may be enhanced by thiazides.
Antikolinerge midler (f. eks. atropin, biperiden) kan øge biotilgængeligheden for diuretika af thiazidtypen ved at reducere den gastrointestinale motilitet og mavetømningshastighed.
Anticholinergic agents (e. g. atropine, biperiden) may increase the bioavailability of thiazide- type diuretics by decreasing gastrointestinal motility and stomach-emptying rate.
7 lægemidlers renale udskillelse (f. eks. cyclofosfamid, methotrexat) og potentiere deres myelosuppressive virkninger.
Thiazides may reduce the renal excretion of cytotoxic medicinal products (e. g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.
Graviditet Der foreligger ikke tilstrækkelige data om brugen af aliskiren hos gravide kvinder.
Pregnancy There are no data on the use of aliskiren in pregnant women.
5. 3).
Aliskiren was not teratogenic in rats or rabbits (see section 5.3).
Andre stoffer, som virker direkte på RAS, associeres imidlertid med alvorlige fostermisdannelser og dødsfald hos nyfødte, når det anvendes i andet og tredje trimester.
Other substances that act directly on the RAS have been associated with serious foetal malformations and neonatal death when used during second and third trimesters.
Langvarig eksponering over for thiazider i 3. trimester af graviditeten kan reducere moderens plasmamængde samt den uteroplacentale blodstrøm, hvilket kan forårsage føto- placental iskæmi og væksthæmning.
7 Prolonged exposure to thiazides during the third trimester of pregnancy can reduce maternal plasma volume as well as uteroplacental blood flow, which may cause a foeto-placental ischaemia and growth retardation.
Ved eksponering lige før fødslen er der endvidere blevet rapporteret om sjældne tilfælde af hypoglykæmi og trombocytopeni hos neonatale.
Moreover, rare cases of hypoglycaemia and thrombocytopenia in neonates have been reported following exposure near term.
Rasilez HCT er kontraindiceret i 2. og 3. trimester af graviditeten (se pkt.
No specific clinical studies have been performed with this combination, therefore Rasilez HCT should not be used during the first trimester of pregnancy or in women planning to become pregnant and is contraindicated during the second and third trimesters (see section 4.3).
4. 3).
Lactation Rasilez HCT is contraindicated during lactation (see section 4.3).
Thiazider ses i human modermælk og kan hæmme laktation.
Thiazides appear in human milk and may inhibit lactation.
De kan medføre utilsigtede, biologiske virkninger, herunder hypokaliæmi, hæmolyse (glukose- 6- phosphat dehydrogenase (G6PD) defekt) og overfølsomhed pga. de sulfonamide egenskaber.
They can produce adverse biological effects including hypokalaemia, haemolysis (glucose-6-phosphate dehydrogenase (G6PD) defect) and hypersensitivity due to sulphonamide properties.
Det er usandsynligt, at Rasilez HCT påvirker evnen til at føre motorkøretøj eller betjene maskiner.
Rasilez HCT is unlikely to affect the ability to drive and use machines.
Aliskiren/ hydrochlorthiazid- kombination Rasilez HCT' s sikkerhed er blevet evalueret i 9 kliniske forsøg med mere end 3. 900 patienter, herunder over 700 behandlet i over 6 måneder og 190 i over 1 år.
Aliskiren/ hydrochlorothiazide combination The safety of Rasilez HCT has been evaluated in 9 clinical trials with more than 3,900 patients, including over 700 treated for over 6 months, and 190 for over 1 year.
Hyppigheden af bivirkninger ved behandling med Rasilez HCT i doser op til 300 mg/ 25 mg svarede overordnet til placebos.
Treatment with Rasilez HCT had an overall incidence of adverse experiences at doses up to 300 mg/ 25 mg similar to placebo.
Meget almindelig (≥ 1/ 10), almindelig (≥ 1/ 100 til < 1/ 10), ikke almindelig (≥ 1/ 1. 000 til < 1/ 100), sjælden (≥ 1/ 10. 000 til < 1/ 1. 000), meget sjælden (< 1/ 10. 000), ikke kendt (kan ikke estimeres ud fra forhåndenværende data).
The frequency of adverse reactions listed below is defined using the following convention: very common (≥ 1/ 10); common (≥ 1/ 100 to < 1/ 10); uncommon (≥ 1/ 1,000 to < 1/ 100); rare (≥ 1/ 10,000 to < 1/ 1,000); very rare (< 1/ 10,000), not known (cannot be estimated from the available data).
8 Diarré:
Diarrhoea:
Diarré er en dosisrelateret bivirkning af aliskiren.
Diarrhoea is a dose-related adverse drug reaction for aliskiren.
I kontrollerede, kliniske forsøg var incidensen af diarré hos Rasilez HCT- behandlede patienter 1, 3%, sammenlignet med 1, 4% for aliskiren - eller 1, 9% for hydrochlorthiazidbehandlede patienter.
In controlled clinical trials, the incidence of diarrhoea in Rasilez HCT-treated patients was 1.3% compared to 1.4% for aliskiren- or 1.9% for hydrochlorothiazide-treated patients.
I et stort, placebo- kontrolleret, klinisk forsøg opvejede de modsatte virkninger af aliskiren (150 mg eller 300 mg) og hydrochlorthiazid (12, 5 mg eller 25 mg) mht. serumkalium omtrent hinanden hos mange patienter.
In a large placebo-controlled clinical trial, the opposite effects of aliskiren (150 mg or 300 mg) and hydrochlorothiazide (12.5 mg or 25 mg) on serum potassium approximately balanced each other in many patients.
4. 4 og 4. 5).
Periodic determinations of serum potassium to detect possible electrolyte imbalance should be performed in patients at risk at appropriate intervals (see sections 4.4 and 4.5).
Yderligere oplysninger om individuelle komponenter Bivirkninger, der tidligere er blevet indberettet for en af de individuelle komponenter, kan forekomme med Rasilez HCT, selvom de ikke er blevet observeret i kliniske forsøg.
8 Additional information on individual components Adverse reactions previously reported with one of the individual components may occur with Rasilez HCT even if not observed in clinical trials.
Aliskiren Behandling med Aliskiren op til 300 mg resulterede i en generel incidens af bivirkninger, der svarede til placebo.
Aliskiren Treatment with Aliskiren up to 300 mg resulted in an overall incidence of adverse reactions similar to placebo.
Udslæt Angioødem
Rash Angioedema
I kontrollerede kliniske studier forekom angioødem sjældent under behandling med aliskiren, og havde sammenlignelig incidens med placebo eller hydrochlorthiazid.
In controlled clinical trials, angioedema occurred rarely during treatment with aliskiren with rates comparable to treatment with placebo or hydrochlorothiazide.
Tilfælde af angioødem er også rapporteret efter markedsføring (incidens ikke kendt).
Cases of angioedema have also been reported in post-marketing experience (frequency unknown).
4. 4).
In the event of any signs suggesting an allergic reaction patients should discontinue treatment and contact the physician (see section 4.4).
For patienter, der blev behandlet med placebo (0, 6%), svarede incidensen af hoste til incidensen for patienter, der blev behandlet med aliskiren (0, 9%).
The incidence of cough was similar in placebo (0.6%) and aliskiren-treated (0.9%) patients.
Denne virkning ses også med andre stoffer, som virker på RAS, såsom ACE- hæmmere og angiotensin- II- antagonister.
This effect is also seen with other agents acting on the RAS, such as ACEIs and angiotensin receptor blockers.
Stigninger i serumkalium var minimale og usædvanelige hos patienter med essentiel hypertension, som blev behandlet med aliskiren alene (0, 9% kontra 0, 6% med placebo).
Increases in serum potassium were minor and infrequent in patients with essential hypertension treated with aliskiren alone (0.9% compared to 0.6% with placebo).
I et studie, hvor aliskiren blev anvendt sammen med en ACE- hæmmer i en diabetisk population, var stigningerne i serumkalium dog mere hyppige (5, 5%).
However, in one study where aliskiren was used in combination with an ACEI in a diabetic population, increases in serum potassium were more frequent (5.5%).
Derfor er rutinemæssig monitorering af elektrolytter og nyrefunktion som ved andre stoffer, der virker på RAS- systemet, indiceret i patienter med diabetes mellitus, nyresygdom eller hjertesvigt.
Therefore, as with any agent acting on the RAS, routine monitoring of electrolytes and renal function is indicated in patients with diabetes mellitus, kidney disease, or heart failure.
4. 4).
In post-marketing experience, renal dysfunction and cases of acute renal failure have been reported in patients at risk (see section 4.4).
9 Hydrochlorthiazid Rapporterede bivirkninger (uanset forhold til lægemidlet) ved anvendelsen af hydrochlorthiazid alene omfatter:
Hydrochlorothiazide Adverse events (regardless of relationship to medicinal product) reported with the use of hydrochlorothiazide alone include:
Blod og lymfesystem
9 Blood and lymphatic system disorders
Aplastisk anæmi, knoglemarvsdepression, neutropeni/ agranulocytose, hæmolytisk anæmi, leukopeni, trombocytopeni
Aplastic anaemia, bone marrow depression, neutropenia/ agranulocytosis, haemolytic anaemia, leucopenia, thrombocytopenia
Nervesystemet Øjne
Nervous system disorders
Rastløshed, uklarhed, vertigo, paræstesi, svimmelhed
Restlessness, light-headedness, vertigo, paraesthesia, dizziness
Forbigående sløret syn, xanthopsi
Transient blurred vision, xanthopsia
Åndedrætsbesvær (herunder pneumoni og lungeødem)
Respiratory distress (including pneumonitis and pulmonary oedema)
Pancreatitis, anoreksi, diarré, forstoppelse, maveirritation, sialoadenitis, appetitløshed
Pancreatitis, anorexia, diarrhoea, constipation, gastric irritation, sialadenitis, loss of appetite
Lever
Hepatobiliary disorders
og galdeveje Ikke kendt:
Not known:
Icterus (intrahepatisk icterus med cholestasis)
Jaundice (intrahepatic cholestatic jaundice)
Anafylaktiske reaktioner, toksisk epidermal nekrolyse, nekrotiserende angiitis (vasculitis, kutan vasculitis), kutan lupus erythematosus - lignende reaktioner, reaktivering af kutan lupus erythematosus, fotosensitivitetsreaktioner, udslæt, urticaria
Anaphylactic reactions, toxic epidermal necrolysis, necrotising angiitis (vasculitis, cutaneous vasculitis), cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus, photosensitivity reactions, rash, urticaria
Knogler, led, muskler og bindevæv Nyrer
Musculoskeletal and connective tissue disorders
Ikke kendt: og urinveje Ikke kendt:
Not known:
Svaghed, muskelkrampe Interstitiel nefritis, renal dysfunktion
Interstitial nephritis, renal dysfunction
4. 4), hyperurikæmi, glykosuri, hyperglykæmi, stigninger i kolesterol og triglycerider
Electrolyte imbalance, including hypokalaemia and hyponatraemia (see section 4.4), hyperuricaemia, glycosuria, hyperglycaemia, increases in cholesterol and triglycerides
Der er ikke rapporteret om tilfælde af overdosering med Rasilez HCT.
No information is available on the treatment of overdose with Rasilez HCT.
Hypokaliæmi kan resultere i muskelspasmer og/ eller forstærke hjertearytmier forbundet med samtidig brug af digitalis glykosider eller visse anti - arytmiske lægemidler.
Hypokalaemia may result in muscle spasms and/ or accentuate cardiac arrhythmias associated with the concomitant use of digitalis glycosides or certain antiarrhythmic medicinal products.
Reninhæmmer (aliskiren) kombinationer med diuretika (hydrochlorthiazid), ATC- kode:
Renin inhibitor (aliskiren) combinations with diuretics (hydrochlorothiazide), ATC code:
Rasilez HCT kombinerer to antihypertensive komponenter til kontrol af blodtryk hos patienter med essentiel hypertension:
10 Rasilez HCT combines two antihypertensive compounds to control blood pressure in patients with essential hypertension:
Aliskiren tilhører klassen af direkte reninhæmmere og hydrochlorthiazid tilhører klassen af thiaziddiuretika.
Aliskiren belongs to the class of direct renin inhibitors and hydrochlorothiazide to the class of thiazide diuretics.
Aliskiren Aliskiren er en oral aktiv, non- peptid, potent, selektiv og direkte hæmmer af humant renin.
Aliskiren Aliskiren is an orally active, non-peptide, potent and selective direct inhibitor of human renin.
Ved at hæmme enzymet renin hæmmer aliskiren renin- angiotensin systemet (RAS) ved aktiveringspunktet og blokerer konverteringen af angiotensinogen til angiotensin I og mindsker niveauet af angiotensin I og angiotensin II.
By inhibiting the enzyme renin, aliskiren inhibits the renin-angiotensin system (RAS) at the point of activation, blocking the conversion of angiotensinogen to angiotensin I and decreasing levels of angiotensin I and angiotensin II.
50- 80%.
Whereas other agents that inhibit the RAS (angiotensin converting enzyme inhibitors (ACEI) and angiotension II receptor blockers (ARB)) cause a compensatory rise in plasma renin activity (PRA), treatment with aliskiren decreases PRA in hypertensive patients by approximately 50 to 80%.
Hos hypertensive patienter gav administration af aliskiren en gang dagligt i doser på 150 mg og 300 mg dosisafhængige reduktioner i både det systoliske og det diastoliske blodtryk, som blev opretholdt over hele dosisintervallet på 24 timer (med vedvarende gavnlig virkning tidligt om morgenen) med en gennemsnitlig peak/ trough ratio for diastolisk respons på op til 98% for 300 mg - dosen.
In hypertensive patients, once-daily administration of aliskiren at doses of 150 mg and 300 mg provided dose-dependent reductions in both systolic and diastolic blood pressure that were maintained over the entire 24-hour dose interval (maintaining benefit in the early morning) with a mean peak to trough ratio for diastolic response of up to 98% for the 300 mg dose.
I et 6 måneders studie med 599 hypertensionspatienter med type 2 diabetes mellitus og nefropati, der alle fik 100 mg losartan sammen med optimal antihypertensiv standardbehandling, opnåedes ved tillæg af aliskiren 300 mg en 20% reduktion i forhold til placebo i urin- albumin- kreatininforholdet (UACR), dvs. fra 58 mg/ mmol to 46 mg/ mmol.
In a 6-month study of 599 patients with hypertension, type 2 diabetes mellitus and nephropathy, all of whom were receiving losartan 100 mg and optimised antihypertensive background therapy, addition of aliskiren 300 mg achieved a 20% reduction versus placebo in urinary albumin: creatinine ratio (UACR), i. e. from 58 mg/ mmol to 46 mg/ mmol.
Andelen af patienter, som fik UACR reduceret med mindst 50% fra baseline ved forsøgets slutning var henholdsvis 24, 7% for aliskiren og 12, 5% for placebo.
The proportion of patients who had UACR reduced at least 50% from baseline to endpoint was 24.7% and 12.5% for aliskiren and placebo, respectively.
Aliskiren påvirkede ikke serumkoncentrationen af kreatinin men blev forbundet med en øget frekvens (4, 2% vs.
Aliskiren did not affect the serum concentration of creatinine but was associated with an increased frequency (4.2% vs.
I et 3 måneders studie med 302 patienter med mildt, stabilt hjertesvigt, som alle var i standardbehandling for stabilt hjertesvigt, blev tillæg af aliskiren 150 mg godt tolereret.
In a 3-month study of 302 patients with mild stable heart failure, all of whom were receiving standard therapy for stable heart failure, addition of aliskiren 150 mg was well tolerated.
Niveauet for natriuretisk peptid (BNP) type B blev nedsat med 25% i aliskiren- armen sammenlignet med placebo.
B-type natriuretic peptide (BNP) levels were reduced by 25% in the aliskiren arm compared to placebo.
Studier med kombinationsbehandling er tilgængelige, hvor aliskiren blev tilføjet diuretisk hydrochlorthiazid, ACE- hæmmeren ramipril, calciumkanalblokkeren amlodipin, AIIA' eren valsartan og betablokkeren atenolol.
Combination therapy studies are available for aliskiren added to the diuretic hydrochlorothiazide, the ACEI ramipril, the calcium channel blocker amlodipine, the ARB valsartan, and the beta blocker atenolol.
11 Hydrochlorthiazid Thiaziddiuretikas virkningspunkt er primært i nyrens tubulus contortus distalis.
Hydrochlorothiazide The site of action of thiazide diuretics is primarily in the renal distal convoluted tubule.
Det er blevet påvist, at der er en højaffinitetsreceptor i renal cortex som det primære bindingssted for den thiaziddiuretiske virkning og hæmning af NaC1- transport i tubulus contortus distalis.
It has been shown that there is a high-affinity receptor in the renal cortex as the primary binding site for the thiazide diuretic action and inhibition of NaCl transport in the distal convoluted tubule.
Thiaziders virkningsmåde er gennem hæmning af Na+Cl - symporteren ved at konkurrere om Cl- bindingsstedet, hvorved elektrolytreabsorptionsmekanismerne påvirkes: ved direkte at øge natrium - og kloridudskillelse i omtrent lige omfang og indirekte ved, at denne diuretiske virkning reducerer plasmavolumen med efterfølgende stigninger i plasmareninaktivitet, aldosteronudskillelse og urinkaliumtab samt en reduktion i serumkalium.
The mode of action of thiazides is through inhibition of the Na+Cl- symporter by competing for the Cl- site, thereby affecting electrolyte reabsorption mechanisms: directly increasing sodium and chloride excretion to an approximately equal extent, and indirectly by this diuretic action reducing plasma volume, with
Aliskiren/ hydrochlorthiazid Mere end 3. 900 hypertensive patienter har fået Rasilez HCT en gang dagligt i kliniske forsøg.
Aliskiren/ hydrochlorothiazide Over 3,900 hypertensive patients received Rasilez HCT once daily in clinical trials.
Hos hypertensive patienter gav administration af Rasilez HCT én gang dagligt dosis- afhængige reduktioner i både systolisk og diastolisk blodtryk, som blev vedligeholdt i hele 24- timers dosisintervallet.
In hypertensive patients, once-daily administration of Rasilez HCT provided dose-dependent reductions in both systolic and diastolic blood pressure that were maintained over the entire 24-hour dose interval.
Den blodtrykssænkende virkning blev opretholdt ved langtidsbehandling og var uafhængig af alder, køn, BMI og etnicitet.
The antihypertensive effect is largely manifested within 1 week and the maximum effect is generally seen within 4 weeks. The blood-pressure-lowering effect was sustained during long-term treatment, and was independent of age, gender, body mass index and ethnicity.
Ved ophør af aliskirenbehandlingen (aliskiren med eller uden tillæg af hydrochlorthiazid) vendte blodtrykket gradvist tilbage til udgangspunktet (over 3- 4 uger) uden tegn på reboundeffekt.
Upon withdrawal of the aliskiren treatment (aliskiren with or without hydrochlorothiazide add-on), the return of blood pressure towards baseline was gradual (3-4 weeks) with no evidence of the rebound effect.
Rasilez HCT blev undersøgt i et placebokontrolleret forsøg, som inkluderede 2. 762 hypertensive patienter med diastolisk blodtryk ≥ 95 mmHg og < 110 mmHg (middel baselineblodtryk på 153, 6/ 99, 2 mmHg).
Rasilez HCT was studied in a placebo-controlled trial including 2,762 hypertensive patients with diastolic blood pressure ≥ 95 mmHg and < 110 mmHg (mean baseline blood pressure of 153.6/ 99.2 mmHg).
I dette studie viste Rasilez HCT i doser fra 150 mg/ 12, 5 mg til 300 mg/ 25 mg dosisafhængige blodtryksreduktioner (systolisk/ diastolisk) fra henholdsvis 17, 6/ 11, 9 mmHg til 21, 2/ 14, 3 mmHg, sammenlignet med 7, 5/ 6, 9 mmHg for placebo.
In this study, Rasilez HCT in doses from 150 mg/ 12.5 mg to 300 mg/ 25 mg produced dose-dependent blood pressure reductions (systolic/ diastolic) from 17.6/ 11.9 mmHg to 21.2/ 14.3 mmHg, respectively, compared to 7.5/ 6.9 mmHg with placebo.
Ved administration til hypertensive patienter med markant forhøjet blodtryk (systolisk blodtryk ≥ 160 mmHg og/ eller diastolisk blodtryk ≥ 100 mmHg), viste Rasilez HCT i doser fra 150 mg/ 12, 5 mg til 300 mg/ 25 mg, der blev givet uden optitrering fra monoterapi, signifikant større og hurtigere systolisk/ diastolisk blodtrykskontrol (< 140/ 90 mmHg) sammenlignet med de respektive monoterapier.
When administered in hypertensive patients with markedly elevated blood pressure (systolic blood pressure ≥ 160 mmHg and/ or diastolic blood pressure ≥ 100 mmHg), Rasilez HCT in doses from 150 mg/ 12.5 mg to 300 mg/ 25 mg administered without up-titration from monotherapy demonstrated significantly greater systolic/ diastolic blood pressure control rates (< 140/ 90 mmHg) as compared to the respective monotherapies.
I denne population gav Rasilez HCT 150 mg/ 12, 5 mg til 300 mg/ 25 mg en dosisafhængig systolisk/ diastolisk blodtryksreduktion fra 20, 6/ 12, 4 mmHg til 24, 8/ 14, 5 mmHg, som var signifikant overlegen i forhold til de respektive monoterapier.
In this population, Rasilez HCT 150 mg/ 12.5 mg to 300 mg/ 25 mg provided dose-dependent systolic/ diastolic blood pressure reduction from 20.6/ 12.4 mmHg to 24.8/ 14.5 mmHg, which were significantly superior to the respective monotherapies.